Related Experiment Videos
Evolution of BFM trials for childhood ALL
1Department of Pediatric Hematology and Oncology, Hannover Medical School, 30625 Hannover, Germany.
Annals of Hematology
|May 6, 2004
Summary
Pediatric acute lymphoblastic leukemia (ALL) treatment aims to reduce relapses. Early detection of minimal residual disease (MRD) using gene rearrangements helps identify high-risk patients for tailored therapy, improving outcomes.
Area of Science:
- Pediatric Oncology
- Hematology
- Molecular Biology
Background:
- Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
- Intensive therapy cures up to 80% of pediatric ALL patients.
- Disease recurrence remains the primary cause of treatment failure.
Purpose of the Study:
- To improve risk-adapted therapy for pediatric ALL.
- To reduce relapse rates and treatment morbidity.
- To identify more specific predictors of relapse than early prednisone response.
Main Methods:
- Assessed early in vivo treatment response using prednisone (PRED) and intrathecal methotrexate.
- Identified PRED poor responders ( >1,000 blasts/microL at day 8).
- Utilized minimal residual disease (MRD) detection via T-cell receptor (TCR) or immunoglobulin (Ig) gene rearrangements.
Main Results:
- PRED poor responders had a ~35% cure rate vs. ~80% for adequate responders.
- Many relapses occurred in initially "good risk" subgroups, indicating PRED response limitations.
- MRD detection offers more specific identification of patients at high risk for relapse.
Conclusions:
- MRD detection is a more specific predictor of relapse in pediatric ALL.
- Treatment can be reduced for patients with fast leukemia clearance (good MRD response).
- Treatment intensification is indicated for patients with persistent disease (poor MRD response).